We evaluated the immunogenicity and efficacy of hepatitis B vaccine (Heptavax-B) in a randomized, double-blind, placebo-controlled trial involving 1311 patients receiving hemodialysis in the United States. After three doses of vaccine (40 micrograms each) had been administered, 63 per cent of the patients were antibody-positive. After correction for possible passive transfer of antibodies by blood transfusion, only 50 per cent of vaccine recipients were considered vaccine responders. The incidence of hepatitis B viral infection during the 25 months of the trial was much lower than had been anticipated and was virtually the same in the vaccine and placebo recipients (6.4 and 5.4 per cent, respectively). Four cases of hepatitis B occurred in patients who had an apparent antibody response to the vaccine, but in each case either antibody had reached low or undetectable levels before hepatitis B surface antigen was detected or the patient had been receiving immunosuppressive therapy. This study did not demonstrate the efficacy of the vaccine in a population of patients receiving dialysis in whom both the rate of antibody response to hepatitis B vaccine and the viral attack rate were low. Other measures to control transmission of hepatitis B virus in dialysis units, including surveillance for hepatitis B surface antigen and isolation of patients who are positive for the antigen, must be continued.
This article has been cited by other articles:
Litjens, N. H. R., Huisman, M., van den Dorpel, M., Betjes, M. G. H.
(2008). Impaired Immune Responses and Antigen-Specific Memory CD4+ T Cells in Hemodialysis Patients. J. Am. Soc. Nephrol.
19: 1483-1490
[Abstract][Full Text]
Verkade, M. A., van Druningen, C. J., Vaessen, L. M. B., Hesselink, D. A., Weimar, W., Betjes, M. G. H.
(2007). Functional impairment of monocyte-derived dendritic cells in patients with severe chronic kidney disease. Nephrol Dial Transplant
22: 128-138
[Abstract][Full Text]
Thanavala, Y., Mahoney, M., Pal, S., Scott, A., Richter, L., Natarajan, N., Goodwin, P., Arntzen, C. J., Mason, H. S.
(2005). Immunogenicity in humans of an edible vaccine for hepatitis B. Proc. Natl. Acad. Sci. USA
102: 3378-3382
[Abstract][Full Text]
Karayiannis, P., Main, J., Thomas, H. C.
(2004). Hepatitis vaccines. Br Med Bull
70: 29-49
[Full Text]
Eardley, K. S., Jones, H. E., Osman, H., Smith, S. A.
(2002). Efficacy of the accelerated hepatitis B vaccination schedule used in haemodialysis patients post-exposure to virus: a single-centre experience. Nephrol Dial Transplant
17: 1982-1987
[Abstract][Full Text]
Fleischmann, E. H., Kruppenbacher, J., Bock, H. L., Weber, M.
(2002). Active immunization against hepatitis A in dialysis patients. Nephrol Dial Transplant
17: 1825-1828
[Abstract][Full Text]
Meier, P., Dayer, E., Blanc, E., Wauters, J.-P.
(2002). Early T Cell Activation Correlates with Expression of Apoptosis Markers in Patients with End-Stage Renal Disease. J. Am. Soc. Nephrol.
13: 204-212
[Abstract][Full Text]
Fernandez-Fresnedo, G., Ramos, M. A., Gonzalez-Pardo, M. C., de Francisco, A. L. M., Lopez-Hoyos, M., Arias, M.
(2000). B lymphopenia in uraemia is related to an accelerated in vitro apoptosis and dysregulation of Bcl-2. Nephrol Dial Transplant
15: 502-510
[Abstract][Full Text]
Le Meur, Y., Lorgeot, V., Aldigier, J.-C., Wijdenes, J., Leroux-Robert, C., Praloran, V.
(1999). Whole blood production of monocytic cytokines (IL-1{beta}, IL-6, TNF-{alpha}, sIL-6R, IL-1Ra) in haemodialysed patients. Nephrol Dial Transplant
14: 2420-2426
[Abstract][Full Text]
Kuo, G, Choo, Q., Alter, H., Gitnick, G., Redeker, A., Purcell, R., Miyamura, T, Dienstag, J., Alter, M., Stevens, C., et, al.
(1989). An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science
244: 362-364
[Abstract]
Reese, C. E., Ockner, R. K.
(1989). Prevention of Hepatitis B in Surgeons and Their Patients. PERSPECT VASC SURG ENDOVASC THER
2: 138-147
Previous
